Abstract: A method, a computing device, and a non-transitory machine-readable medium for managing modes of operation for volumes in a node. A first portion of a plurality of volumes in a node is selected to operate in an active mode. A second portion of the plurality of volumes in the node is selected to operate in a passive mode. The second portion of the volumes that operates in the passive mode consumes fewer resources than the first portion of the volumes that operates in the active mode. The first portion of the plurality of volumes and the second portion of the plurality of volumes are adjusted over time based on activity of each volume of the plurality of volumes.

Abstract: A method, a computing device, and a non-transitory machine-readable medium for managing modes of operation for volumes in a node. A first portion of a plurality of volumes in a node is selected to operate in an active mode. A second portion of the plurality of volumes in the node is selected to operate in a passive mode. The second portion of the volumes that operates in the passive mode consumes fewer resources than the first portion of the volumes that operates in the active mode. The first portion of the plurality of volumes and the second portion of the plurality of volumes are adjusted over time based on activity of each volume of the plurality of volumes.

Abstract: Provided herein are methods relating to a therapeutic strategy for treatment of cancer, including hematological malignancies. In particular, the methods include administration of a Btk inhibitor and a checkpoint inhibitor, including combinations in which the Btk inhibitor is 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one, or a pharmaceutically acceptable salt thereof, and the checkpoint inhibitor is selected from inhibitors of PD-1, PD-L1, and CTLA-4.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.

Abstract: Alignment of a receiver clock signal with a transmitter clock signal based upon a received data signal is disclosed. Some embodiments generate, based upon of phase bits and valid phase bits, a phase signal having a voltage level selected from at least three voltage levels. One voltage level corresponds to shifting the receiver clock signal in a first direction. Another voltage level corresponds to shifting the receiver clock signal in a second direction. The other voltage level corresponds to repeating a previous shift of the receiver clock signal.

Abstract: Alignment of a receiver clock signal with a transmitter clock signal based upon a received data signal is disclosed. Some embodiments generate, based upon of phase bits and valid phase bits, a phase signal having a voltage level selected from at least three voltage levels. One voltage level corresponds to shifting the receiver clock signal in a first direction. Another voltage level corresponds to shifting the receiver clock signal in a second direction. The other voltage level corresponds to repeating a previous shift of the receiver clock signal.